Experimental autoimmune encephalomyelitis repressed by microglial paralysis

Frank L Heppner1, Melanie Greter, Denis Marino

  • 1Institute of Neuropathology, University Hospital Zurich, CH-8091 Zurich, Switzerland.

Nature Medicine
|January 25, 2005
PubMed

Insights

Targeting microglia, the immune cells of the central nervous system (CNS), can halt inflammatory CNS diseases. This study validates CD11b-HSVTK mice as a tool to explore microglial roles in CNS disorders.

Area of Science:

  • Neuroimmunology
  • Central Nervous System (CNS) Disorders
  • Cellular Biology

Background:

  • Microglial activation is observed in various CNS disorders, but its precise role in disease pathogenesis remains unclear.
  • Understanding microglial function is crucial for developing targeted therapies for inflammatory CNS conditions.

Purpose of the Study:

  • To investigate the role of microglial activation in the pathogenesis of inflammatory central nervous system (CNS) disorders.
  • To validate CD11b-HSVTK transgenic mice as a model for studying microglial function in CNS diseases.

Main Methods:

  • Generation of CD11b-HSVTK transgenic mice expressing herpes simplex thymidine kinase in macrophages and microglia.
  • Treatment with ganciclovir to selectively eliminate or inhibit microglia.
  • Analysis of microglial activation markers and inflammatory responses in brain slice cultures and in vivo models (axotomy, experimental autoimmune encephalomyelitis).
  • Bone marrow chimera experiments to assess hematopoietic toxicity and microglial-specific effects.

Main Results:

  • Ganciclovir treatment abolished microglial release of inflammatory mediators (nitrite, cytokines, chemokines) in vitro.
  • Systemic ganciclovir administration in CD11b-HSVTK mice led to hematopoietic toxicity, preventable by wild-type bone marrow transfer.
  • Ganciclovir administration in bone marrow chimeras blocked microglial activation post-axotomy and repressed experimental autoimmune encephalomyelitis development.
  • Microglial paralysis effectively inhibited the development and maintenance of inflammatory CNS lesions.

Conclusions:

  • Microglial activation plays a significant role in the development and progression of inflammatory CNS disorders.
  • Targeting the microglial compartment offers a potential therapeutic strategy for inflammatory CNS diseases.
  • CD11b-HSVTK mice serve as a valuable tool for in vivo studies on the impact of microglial activation in CNS pathology.

Related Concept Videos

Encephalitis l: Introduction01:19

Encephalitis l: Introduction

Encephalitis is inflammation of the brain parenchyma, most often due to infections or autoimmune processes. It presents with neuropsychiatric features such as fever, altered mental status, behavioral changes, cognitive dysfunction, seizures, focal deficits, and sometimes autonomic instability. In some cases, the meninges are also involved, resulting in meningoencephalitis.Infectious CausesInfectious encephalitis is most commonly viral but can also result from bacterial, fungal, or parasitic...
15
Encephalitis ll: Pathophysiology01:26

Encephalitis ll: Pathophysiology

Encephalitis is inflammation of the brain parenchyma caused by direct viral invasion or immune-mediated mechanisms triggered by infections or tumors. Both processes lead to neuronal injury, disrupted neurotransmission, and diverse neurological symptoms, often with overlapping clinical and pathological features.Autoimmune EncephalitisIn autoimmune encephalitis, antibodies target neuronal antigens on cell surfaces, synapses, or within neurons. A key example is anti-NMDAR encephalitis, which can...
22
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
53